BIIB - Biogen Is Next In Line With Purchase Of Gene Therapy Biotech
Biogen (BIIB) announced that it would acquire Nightstar Therapeutics (NITE) for $25.50 per share. All said and done this purchase was worth $800 million. This latest deal by Biogen highlights the hype about either partnering with or acquiring gene therapy biotechs. That's because they offer potential for a one-off treatment. The enticement is that gene therapies are able to correct a defective gene in diseases that produce abnormal proteins. There are some risks that remain with these types of treatments, but I will admit that they offer massive potential compared to